debrisoquin and metoprolol

debrisoquin has been researched along with metoprolol in 41 studies

Research

Studies (41)

Timeframe	Studies, this research(%)	All Research%
pre-1990	21 (51.22)	18.7374
1990's	13 (31.71)	18.2507
2000's	7 (17.07)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Iyun, AO; Jackson, PR; Lennard, MS; Tucker, GT; Woods, HF	1
Chiba, K; Ishizaki, T; Jang, IJ; Kusaka, M; Shin, SG; Sohn, DR	1
Jonkers, RE; Koopmans, RP; Portier, EJ; van Boxtel, CJ	1
Adams, M; Lennard, MS; Otton, SV; Tucker, GT; Woods, HF	1
Jackson, PR; Lennard, MS; Lewis, RV; Ramsay, LE; Tucker, GT; Yeo, WW	1
Horai, Y; Ishikawa, K; Ishizaki, T; Taga, J	1
Avenant, J; Moncrieff, J; Sommers, DK	2
Iyun, AO; Lennard, MS; Silas, JH; Tucker, GT; Woods, HF	1
Smith, RL	1
Lennard, MS; McGourty, JC; Silas, JH; Tucker, GT; Woods, HF	2
Lennard, MS; Silas, JH; Tucker, GT; Woods, HF	1
Crewe, HK; Lennard, MS; Tucker, GT; Woods, HF	1
Crewe, HK; Lennard, MS; Otton, SV; Tucker, GT; Woods, HF	1
Babany, G; Benhamou, JP; Degott, C; Heller, F; Henrion, J; Larrey, D; Pessayre, D	1
Dayer, P; Leemann, T; Meyer, UA	1
Iyun, AO; Lennard, MS; Tucker, GT; Woods, HF	1
Freestone, S; Lennard, MS; Silas, JH; Trevethick, J	1
Paxton, JW	1
Freestone, S; Lennard, MS; Ramsay, LE; Silas, JH; Tucker, GT; Woods, HF	2
Jack, DB	1
Lennard, MS; Silas, JH	1
Freestone, S; Lennard, MS; Ramsay, LE; Silas, JH	1
al-Hadidi, HF; Irshaid, YM; Rawashdeh, NM	1
Chadwick, IG; Ellis, SW; Haq, I; Jackson, PR; Lennard, MS; Ramsay, LE; Rowland, K; Tucker, GT; Yeo, WW	1
Basci, NE; Bozkurt, A; Isimer, A; Kayaalp, SO	1
Hodjegan, AR; Lennard, MS; Njunju, E; Simooya, OO; Tucker, GT	1
Dayer, P; Devi, KP; Leemann, TD	1
Bertilssons, L; Ekberg, O; Hasler, J; Ingelman-Sundberg, M; Johansson, I; Masimirembwa, C	1
Cerqueira, PM; Cesarino, EJ; Lanchote, VL; Mateus, FH; Mere, Y; Santos, SR	1
Blackburn, MG; Ellis, SW; Harlow, J; Hayhurst, GP; Larsson, C; Lennard, MS; Lightfoot, T; Lim, CK; Mahling, J; Rowland-Yeo, K; Smith, G; Tucker, GT; Wolf, CR	1
Chowdry, J; Ellis, SW; Gross, E; Harlow, J; Hayhurst, GP; Hilton, E; Lennard, MS; Tucker, GT	1
Abdi, YA; Bertilsson, L; Dandara, C; Gustafsson, LL; Hasler, J; Ingelman-Sundberg, M; Sayi, J; Svensson, JO; Wennerholm, A	1
Dorne, JL; Renwick, AG; Slob, W; Walton, K	1
Crewe, KH; Ozdemir, M; Rostami-Hodjegan, A; Tucker, GT	1
Cerqueira, PM; Coelho, EB; Geleilete, TJ; Goldman, GH; Lanchote, VL	1

Trials

8 trial(s) available for debrisoquin and metoprolol

Article	Year
Influence of debrisoquine oxidation phenotype on exercise tolerance and subjective fatigue after metoprolol and atenolol in healthy subjects. British journal of clinical pharmacology, 1991, Volume: 31, Issue:4 Topics: Adult; Atenolol; Debrisoquin; Fatigue; Female; Humans; Male; Metoprolol; Oxidation-Reduction; Phenotype; Physical Endurance	1991
Polymorphic metabolism of metoprolol: clinical studies. European journal of clinical pharmacology, 1985, Volume: 28 Suppl Topics: Blood Pressure; Debrisoquin; Heart Rate; Heterozygote; Humans; Hydroxylation; Kinetics; Metoprolol; Oxidation-Reduction; Phenotype; Polymorphism, Genetic; Stereoisomerism; Structure-Activity Relationship; Time Factors	1985
Comparison of two long-acting preparations of metoprolol with conventional metoprolol and atenolol in healthy men during chronic dosing. British journal of clinical pharmacology, 1982, Volume: 14, Issue:5 Topics: Adult; Atenolol; Debrisoquin; Delayed-Action Preparations; Heart Rate; Humans; Hydroxylation; Kinetics; Male; Metoprolol; Physical Exertion; Propanolamines; Time Factors	1982
Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol. British journal of clinical pharmacology, 1994, Volume: 38, Issue:1 Topics: Adult; Aged; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Humans; Male; Metoprolol; Microsomes, Liver; Middle Aged; Mixed Function Oxygenases; Phenotype; Propranolol; Recombinant Proteins; Saccharomyces cerevisiae	1994
Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients. Chirality, 1999, Volume: 11, Issue:7 Topics: Adult; Aged; Antihypertensive Agents; Area Under Curve; Debrisoquin; Female; Half-Life; Humans; Hypertension; Male; Metoprolol; Middle Aged; Phenotype; Stereoisomerism	1999
The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity. Clinical pharmacology and therapeutics, 2002, Volume: 71, Issue:1 Topics: Adrenergic Agents; Adrenergic beta-Antagonists; Adult; Aged; Alleles; Analgesics, Opioid; Antitussive Agents; Black People; Cytochrome P-450 CYP2D6; Debrisoquin; Dextromethorphan; Female; Genotype; Humans; Isoenzymes; Kinetics; Male; Metoprolol; Middle Aged; Phenotype; Substrate Specificity; White People	2002
Assessment of in vivo CYP2D6 activity: differential sensitivity of commonly used probes to urine pH. Journal of clinical pharmacology, 2004, Volume: 44, Issue:12 Topics: Administration, Oral; Adolescent; Adult; Ammonium Chloride; Cross-Over Studies; Cytochrome P-450 CYP2D6; Debrisoquin; Dextromethorphan; Female; Humans; Hydrogen-Ion Concentration; Male; Methods; Metoprolol; Middle Aged; Molecular Probes; Sodium Bicarbonate; Tablets, Enteric-Coated; Urine	2004
Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients. Journal of clinical pharmacology, 2005, Volume: 45, Issue:12 Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Cytochrome P-450 CYP2D6; Debrisoquin; Female; Humans; Hypertension; Kidney Failure, Chronic; Male; Metoprolol; Middle Aged; Mutation; Stereoisomerism	2005

Other Studies

33 other study(ies) available for debrisoquin and metoprolol

Article	Year
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians. Pharmacogenetics, 1992, Volume: 2, Issue:2 Topics: Adult; Black People; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Debrisoquin; Female; Gene Frequency; Humans; Male; Metoprolol; Mixed Function Oxygenases; Nigeria; Phenotype; Polymorphism, Genetic; Sparteine	1992
Utility of a one-point (3-hour postdose) plasma metabolic ratio as a phenotyping test using metoprolol in two east Asian populations. Therapeutic drug monitoring, 1992, Volume: 14, Issue:3 Topics: Adolescent; Adult; Asian People; Chromatography, High Pressure Liquid; Debrisoquin; Female; Humans; Japan; Korea; Male; Metoprolol; Middle Aged; Oxidation-Reduction; Phenotype	1992
Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers. The Journal of pharmacology and experimental therapeutics, 1991, Volume: 256, Issue:3 Topics: Administration, Oral; Adult; Debrisoquin; Drug Interactions; Female; Humans; Male; Metoprolol; Phenotype; Receptors, Adrenergic, beta; Stereoisomerism; Terbutaline	1991
Assessment of the mouse as an experimental model for studying polymorphic oxidation of the sparteine/debrisoquine type. Biochemical pharmacology, 1991, Jul-25, Volume: 42, Issue:4 Topics: Animals; Debrisoquin; Kinetics; Male; Metoprolol; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Mice, Inbred C57BL; Mice, Inbred CBA; Mice, Inbred DBA; Mice, Inbred NZB; Mice, Inbred Strains; Microsomes, Liver; Models, Biological; Oxidation-Reduction; Phenotype; Polymorphism, Genetic; Sparteine	1991
Correlations among the metabolic ratios of three test probes (metoprolol, debrisoquine and sparteine) for genetically determined oxidation polymorphism in a Japanese population. British journal of clinical pharmacology, 1990, Volume: 29, Issue:1 Topics: Adolescent; Adult; Debrisoquin; Female; Humans; Isoquinolines; Japan; Male; Metoprolol; Middle Aged; Oxidation-Reduction; Polymorphism, Genetic; Sparteine	1990
Metoprolol alpha-hydroxylation polymorphism in the San Bushmen of southern Africa. Human toxicology, 1989, Volume: 8, Issue:1 Topics: Black People; Debrisoquin; Humans; Hydroxylation; Male; Metoprolol; Nigeria; Polymorphism, Genetic; South Africa; White People	1989
Stereoselective metabolism of metoprolol in Caucasians and Nigerians--relationship to debrisoquine oxidation phenotype. British journal of clinical pharmacology, 1989, Volume: 27, Issue:5 Topics: Biotransformation; Black People; Debrisoquin; Humans; Isoquinolines; Metoprolol; Nigeria; Oxidation-Reduction; Phenotype; Stereoisomerism; White People	1989
Non-correlation between debrisoquine and metoprolol polymorphisms in the Venda. Human toxicology, 1989, Volume: 8, Issue:5 Topics: Black People; Chromatography, High Pressure Liquid; Debrisoquin; Female; Humans; Hydroxylation; Isoquinolines; Male; Metoprolol; Phenotype; South Africa	1989
Polymorphic metabolism of the beta-adrenoreceptor blocking drugs and its clinical relevance. European journal of clinical pharmacology, 1985, Volume: 28 Suppl Topics: Adrenergic beta-Antagonists; Animals; Biological Availability; Blood Pressure; Debrisoquin; Ethanolamines; Glucuronates; Humans; Hydroxylation; Kinetics; Lipids; Metoprolol; Phenotype; Polymorphism, Genetic; Propranolol; Solubility; Structure-Activity Relationship; Timolol	1985
Metoprolol metabolism and debrisoquine oxidation polymorphism--population and family studies. British journal of clinical pharmacology, 1985, Volume: 20, Issue:6 Topics: Adrenergic beta-Antagonists; Adult; Aged; Biotransformation; Dealkylation; Debrisoquin; Female; Humans; Isoquinolines; Male; Metoprolol; Middle Aged; Oxidation-Reduction; Pedigree; Phenotype; Polymorphism, Genetic	1985
Debrisoquine polymorphism and the metabolism and action of metoprolol, timolol, propranolol and atenolol. Xenobiotica; the fate of foreign compounds in biological systems, 1986, Volume: 16, Issue:5 Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Debrisoquin; Genetic Variation; Humans; Hypertension; Isoquinolines; Kinetics; Male; Metoprolol; Oxidation-Reduction; Phenotype; Polymorphism, Genetic; Propranolol; Structure-Activity Relationship; Timolol	1986
Metoprolol oxidation by rat liver microsomes. Inhibition by debrisoquine and other drugs. Biochemical pharmacology, 1986, Aug-15, Volume: 35, Issue:16 Topics: Animals; Antipyrine; Cimetidine; Debrisoquin; Guanidines; Isoquinolines; Metoprolol; Microsomes, Liver; Ranitidine; Rats; Rats, Inbred Strains	1986
Use of quinidine inhibition to define the role of the sparteine/debrisoquine cytochrome P450 in metoprolol oxidation by human liver microsomes. The Journal of pharmacology and experimental therapeutics, 1988, Volume: 247, Issue:1 Topics: Cytochrome P-450 Enzyme System; Dealkylation; Debrisoquin; Humans; Hydroxylation; In Vitro Techniques; Isoquinolines; Kinetics; Metoprolol; Microsomes, Liver; Quinidine; Quinine; Sparteine	1988
Metoprolol-induced hepatitis: rechallenge and drug oxidation phenotyping. Annals of internal medicine, 1988, Volume: 108, Issue:1 Topics: Chemical and Drug Induced Liver Injury; Debrisoquin; Female; Humans; Liver Function Tests; Metoprolol; Middle Aged; Oxidation-Reduction; Phenotype	1988
Single-dose quinidine treatment inhibits metoprolol oxidation in extensive metabolizers. European journal of clinical pharmacology, 1986, Volume: 29, Issue:6 Topics: Adult; Debrisoquin; Depression, Chemical; Humans; Metoprolol; Oxidation-Reduction; Quinidine; Stereoisomerism	1986
Metoprolol and debrisoquin metabolism in Nigerians: lack of evidence for polymorphic oxidation. Clinical pharmacology and therapeutics, 1986, Volume: 40, Issue:4 Topics: Adult; Aged; Black People; Debrisoquin; Female; Humans; Hydroxylation; Isoquinolines; Male; Metoprolol; Middle Aged; Nigeria; Phenotype; Polymorphism, Genetic; Random Allocation; White People	1986
Defective metabolism of metoprolol in poor hydroxylators of debrisoquine. British journal of clinical pharmacology, 1982, Volume: 14, Issue:2 Topics: Adrenergic beta-Antagonists; Debrisoquin; Exercise Test; Half-Life; Humans; Hydroxylation; Isoquinolines; Metoprolol; Oxidation-Reduction; Phenotype; Propanolamines	1982
Oxidation phenotype and beta-blockers. The New England journal of medicine, 1983, Apr-21, Volume: 308, Issue:16 Topics: Adrenergic beta-Antagonists; Debrisoquin; Ethanolamines; Humans; Metoprolol; Oxidation-Reduction; Phenotype	1983
Pharmacogenetic polymorphism of drug metabolism. The New Zealand medical journal, 1984, Aug-22, Volume: 97, Issue:762 Topics: Acetylation; Acetyltransferases; Debrisoquin; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxylation; Metoprolol; Oxidation-Reduction; Pharmaceutical Preparations; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Racial Groups; Sparteine; Succinylcholine	1984
Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolizers. Clinical pharmacology and therapeutics, 1983, Volume: 34, Issue:6 Topics: Adult; Chromatography, High Pressure Liquid; Debrisoquin; Humans; Isoquinolines; Kinetics; Male; Metabolic Clearance Rate; Metoprolol; Middle Aged; Phenotype; Stereoisomerism	1983
Statistical analysis of polymorphic drug metabolism data using the Rosin Rammler Sperling Weibull distribution. European journal of clinical pharmacology, 1983, Volume: 25, Issue:4 Topics: Acebutolol; Africa; Debrisoquin; Humans; Isoniazid; Metoprolol; Polymorphism, Genetic; Sparteine; Statistics as Topic	1983
Protecting the poor metaboliser--from what? British journal of clinical pharmacology, 1984, Volume: 17, Issue:4 Topics: Debrisoquin; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxylation; Metoprolol; Pharmaceutical Preparations; Phenotype	1984
Rapid determination of metoprolol and alpha-hydroxymetoprolol in human plasma and urine by high-performance liquid chromatography. Journal of chromatography, 1983, Jan-14, Volume: 272, Issue:1 Topics: Chromatography, High Pressure Liquid; Debrisoquin; Humans; Metoprolol; Propanolamines	1983
Oxidation phenotype--a major determinant of metoprolol metabolism and response. The New England journal of medicine, 1982, Dec-16, Volume: 307, Issue:25 Topics: Debrisoquin; Heart Rate; Humans; Hydroxylation; Male; Metoprolol; Molecular Biology; Oxidation-Reduction; Phenotype; Polymorphism, Genetic; Propanolamines	1982
Metoprolol alpha-hydroxylation is a poor probe for debrizoquine oxidation (CYP2D6) polymorphism in Jordanians. European journal of clinical pharmacology, 1994, Volume: 47, Issue:4 Topics: Administration, Oral; Adolescent; Adult; Debrisoquin; Humans; Hydroxylation; Jordan; Male; Metoprolol; Phenotype; Polymorphism, Genetic	1994
Correlation between the metabolic ratios of debrisoquine and metoprolol in Turkish subjects. Pharmacology & toxicology, 1994, Volume: 75, Issue:1 Topics: Adolescent; Adult; Chromatography, High Pressure Liquid; Debrisoquin; Female; Humans; Male; Metoprolol; Oxidation-Reduction; Phenotype; Turkey	1994
Debrisoquine and metoprolol oxidation in Zambians: a population study. Pharmacogenetics, 1993, Volume: 3, Issue:4 Topics: Adult; Black People; Debrisoquin; Female; Humans; Male; Metoprolol; Oxidation-Reduction; White People; Zambia	1993
Similar effect of oxidation deficiency (debrisoquine polymorphism) and quinidine on the apparent volume of distribution of (+/-)-metoprolol. European journal of clinical pharmacology, 1993, Volume: 45, Issue:1 Topics: Adult; Blood Proteins; Debrisoquin; Drug Interactions; Humans; Male; Metoprolol; Phenotype; Polymorphism, Genetic; Protein Binding; Quinidine	1993
Phenotype and genotype analysis of debrisoquine hydroxylase (CYP2D6) in a black Zimbabwean population. Reduced enzyme activity and evaluation of metabolic correlation of CYP2D6 probe drugs. European journal of clinical pharmacology, 1996, Volume: 51, Issue:2 Topics: Cytochrome P-450 CYP2D6; Debrisoquin; Genetic Variation; Genotype; Humans; Metoprolol; Molecular Probes; Phenotype; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single-Stranded Conformational; Zimbabwe	1996
Evidence that serine 304 is not a key ligand-binding residue in the active site of cytochrome P450 2D6. The Biochemical journal, 2000, Feb-01, Volume: 345 Pt 3 Topics: Alanine; Amino Acid Substitution; Aspartic Acid; Binding Sites; Catalytic Domain; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Enzyme Inhibitors; Kinetics; Ligands; Metoprolol; Mutagenesis, Site-Directed; Oxidation-Reduction; Propranolol; Quinidine; Quinine; Serine; Substrate Specificity; Yeasts	2000
Influence of phenylalanine-481 substitutions on the catalytic activity of cytochrome P450 2D6. The Biochemical journal, 2001, Apr-15, Volume: 355, Issue:Pt 2 Topics: Alkylation; Catalysis; Cytochrome P-450 CYP2D6; Debrisoquin; Dextromethorphan; Kinetics; Metoprolol; Mutagenesis, Site-Directed; Oxidation-Reduction; Phenylalanine; Substrate Specificity	2001
Human variability in polymorphic CYP2D6 metabolism: is the kinetic default uncertainty factor adequate? Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association, 2002, Volume: 40, Issue:11 Topics: Adult; Aged; Aging; Benzhydryl Compounds; Cresols; Cyclohexanols; Cytochrome P-450 CYP2D6; Debrisoquin; Desipramine; Encainide; Ethnicity; Genetic Variation; Humans; Hydroxylation; Infant; Infant, Newborn; Kidney Diseases; Kinetics; Liver Diseases; Metabolic Clearance Rate; Metoprolol; Phenylpropanolamine; Polymorphism, Genetic; Propafenone; Substrate Specificity; Tolterodine Tartrate; Venlafaxine Hydrochloride	2002